Compare Otis Worldwide Corp (OTIS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Otis Worldwide Corp vs Sana Biotechnology Inc — how do they compare? Otis Worldwide Corp trades at $66.26 (market cap $25.17B), while Sana Biotechnology Inc trades at $2.84 (market cap $836.71M). The key difference: Otis Worldwide Corp is far larger — about 30.1× Sana Biotechnology Inc's market cap, and Otis Worldwide Corp pays a 2.66% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Otis Worldwide Corp for 65 Days and Sana Biotechnology Inc for 23 Days on average.
| OTIS | SANA | |
|---|---|---|
Market Cap | $25.17B | $836.71M |
Volume | 4,542,442 | 4,507,444 |
Sector | Industrials | Health |
52-Week High | $93.62 | $5.92 |
52-Week Low | $64.05 | $2.68 |
Typical Hold Time | 65 Days | 23 Days |
Enterprise Value | $33.20B | $749.96M |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Otis Worldwide trades at $66.14, up 0.61% today but near its 52-week low, with technical indicators showing bearish momentum. The company reported mixed Q2 2026 results, missing EPS estimates while maintaining strong service revenue growth. Recent CEO succession news and China market challenges create uncertainty, though analyst consensus remains positive with a $87 price target representing 31% upside potential.
The stock presents a value opportunity with reasonable P/E of 16.99 and P/S of 1.73, but faces margin pressure and execution risks. Service segment growth and modernization backlog provide stability, while weak equipment demand and China exposure remain headwinds. Institutional ownership shows mixed signals with recent buying and selling activity.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
